Drug intelligence / Profile preview

cefpodoxime proxetil + clavulanic acid

Development stage
Unknown
Lead developer
Bengal Biopharma
Modality
Small Molecules
Administration
Oral
01

Overview

Cixpod-CV is a fixed-dose combination antibiotic containing cefpodoxime proxetil, a third-generation cephalosporin, and potassium clavulanate, a beta-lactamase inhibitor. Cefpodoxime proxetil acts as a prodrug that is hydrolyzed to its active form, cefpodoxime, which inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanic acid is included to irreversibly inhibit beta-lactamase enzymes produced by resistant bacteria, thereby protecting cefpodoxime from enzymatic degradation and extending its spectrum of activity. This combination is primarily used for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections. It is marketed as a branded generic formulation by companies such as Bengal Biopharma in the Indian pharmaceutical market.

Brand names
Cixpod-CV
Other names
Cefpodoxime Proxetil and Potassium Clavulanate Tablets
02

Targets

PBP (Penicillin-binding protein family)β-lactamase

Beyond the preview

Go deeper on cefpodoxime proxetil + clavulanic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefpodoxime proxetil + clavulanic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call